These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 28146051)

  • 1. Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.
    Vendrell JA; Mau-Them FT; Béganton B; Godreuil S; Coopman P; Solassol J
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
    Alix-Panabières C; Pantel K
    Cancer Discov; 2016 May; 6(5):479-91. PubMed ID: 26969689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of circulating-tumor DNA analysis in non-small cell lung cancer.
    Jiang T; Ren S; Zhou C
    Lung Cancer; 2015 Nov; 90(2):128-34. PubMed ID: 26415994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
    Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
    Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor cells in patients with lung cancer: developments and applications for precision medicine.
    Tong B; Wang M
    Future Oncol; 2019 Jul; 15(21):2531-2542. PubMed ID: 31339062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq.
    Bratman SV; Newman AM; Alizadeh AA; Diehn M
    Expert Rev Mol Diagn; 2015 Jun; 15(6):715-9. PubMed ID: 25773944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
    Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
    PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid Biopsy and Lung Cancer.
    Pisapia P; Malapelle U; Troncone G
    Acta Cytol; 2019; 63(6):489-496. PubMed ID: 30566947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid Biopsy in the Clinical Management of Cancers.
    Ho HY; Chung KK; Kan CM; Wong SC
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
    Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
    Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma.
    Calapre L; Warburton L; Millward M; Ziman M; Gray ES
    Cancer Lett; 2017 Sep; 404():62-69. PubMed ID: 28687355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-free circulating tumour DNA as a liquid biopsy in breast cancer.
    De Mattos-Arruda L; Caldas C
    Mol Oncol; 2016 Mar; 10(3):464-74. PubMed ID: 26776681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer.
    Takai E; Yachida S
    World J Gastroenterol; 2016 Oct; 22(38):8480-8488. PubMed ID: 27784960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer.
    Moon SM; Kim JH; Kim SK; Kim S; Kwon HJ; Bae JS; Lee S; Lee HS; Choi MY; Jeon BH; Jeong BH; Lee K; Kim HK; Kim J; Um SW
    Anticancer Res; 2020 Jun; 40(6):3435-3444. PubMed ID: 32487642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring.
    Li W; Liu JB; Hou LK; Yu F; Zhang J; Wu W; Tang XM; Sun F; Lu HM; Deng J; Bai J; Li J; Wu CY; Lin QL; Lv ZW; Wang GR; Jiang GX; Ma YS; Fu D
    Mol Cancer; 2022 Jan; 21(1):25. PubMed ID: 35057806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liquid Biopsies for Assessing Metastatic Melanoma Progression.
    Huynh K; Hoon DS
    Crit Rev Oncog; 2016; 21(1-2):141-54. PubMed ID: 27481010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
    Hicks JK; Saller J; Wang E; Boyle T; Gray JE
    Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer.
    He J; Tan W; Ma J
    Future Oncol; 2017 Apr; 13(9):787-797. PubMed ID: 28073294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.